ARIXTRA (Aspen Pharmacare Australia Pty Ltd)
Product name
ARIXTRA
Date registered
Evaluation commenced
Decision date
Approval time
237 working days (255)
Active ingredients
fondaparinux sodium
Registration type
EOI
Indication
ARIXTRA is now also indicated for the treatment of unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI) in patients for whom urgent (<120 min) invasive management (PCI) in not indicated.
ARIXTRA is now also indicated for the treatment of ST segment elevation myocardial infarction (STEMI) in patients who are managed without any form of initial reperfusion therapy.